APAC’s Premier CGT Congress - Uniting Leaders, Innovation, and Quality

Dr. Jimmy Chang is an accomplished biopharmaceutical executive and scientist with over three decades of global experience spanning drug development, clinical development, regulatory strategy, and commercialization. He currently serves as the President and Chief Executive Officer of TaiMed Biologics, a publicly traded company on the Taiwan Stock Exchange and a recognized innovator in HIV treatment.

Under Dr. Chang’s leadership, TaiMed successfully achieved U.S. FDA approval and commercialization of Trogarzo® (ibalizumab)—the world’s first and only long-acting monoclonal antibody for the treatment of HIV, marking a breakthrough in the fight against multidrug-resistant HIV. His strategic vision has helped transform TaiMed from a development-stage enterprise into a fully integrated, commercial-stage biopharmaceutical company. The company now boasts capabilities in antibody innovation, antibody-drug conjugates (ADCs), CDMO services, and operates its own GMP biologics manufacturing facility in Taiwan.

Zach Pang is Group Leader at the Bioprocessing Technology Institute, A*STAR and Senior Scientist at the Bioinformatics Institute, A*STAR, where he leads a research team to drive digitalisation in biomanufacturing. His research interests include mechanistic modelling and process modelling of bioprocesses. He is also Assistant Professor (adj) at NUS Department of Biomedical Engineering and NTU School of Chemistry, Chemical Engineering, and Biotechnology. Zach is also a co-founder and chief scientific advisor of AuctuCel Pte Ltd, a biotech company that develops AI-powered and ready-to-use culture media to improve biomanufacturing yield. 

Zach developed an interest in cross-disciplinary research when he was pursuing his Bachelor of Technology in Mechanical Engineering at the National University of Singapore, where he did his undergraduate research on cancer cell mechanics. He later pursued a PhD in Bioengineering at Imperial College London under the A*STAR Scholarship, and more recently completed a Doctor of Business Administration (DBA) from the Swiss School of Management. Zach Pang also holds a Master of Business Administration from Quantic School of Business and Technology and a postgraduate certificate in learning and teaching in higher education from the University of London. He is a chartered engineer (CEng) with the Engineering Council UK, an associate fellow of the Higher Education Academy, UK (AFHEA) and a member of the Institute of Physics and Engineering in Medicine (MIPEM).

Dr. Warren Chan is the Dean of the College of Engineering and the President’s Chair Professor in Engineering at Nanyang Technological University (NTU). He received his B.S. degree from the University of Illinois in 1996, Ph.D. from Indiana University in 2001, post-doctoral training at the University of California (San Diego). He started as an Assistant Professor at the University of Toronto from 2002, became Full professor in 2012, and the Canadian Research Chair in Nanoengineering. He was the Director of the Institute of Biomedical Engineering before joining NTU. His lab develops nanotechnology for diagnosing and treating cancer and infectious diseases. He is an Executive Editor of ACS Nano. 

A/Prof Bi is a Senior Principal Scientist with over 30 years of research experience in protein analytics and proteomics. He joined A*STAR in 2009 and currently leads the protein analytics group at the Bioprocessing Technology Institute. He works closely with industry partners on streamlined LC-MS technologies for the versatile characterisation of biotherapeutic product quality attributes, as well as on innovative real-time online process analytical technologies and sensors for automated monitoring of process parameters and product quality. Since 2019, he has also served as an Adjunct Associate Professor at Duke-NUS Medical School for clinical proteomics, and since 2023 at the Singapore Institute of Technology for food proteomics.

Dr Paula Lam serves as the Chief Scientific Officer at BioCell Innovations Pte Ltd., a Singapore based start-up company dedicated to advancing cell and gene therapies for patients-in-need. She earned her PhD from University of Leeds in UK majoring in Molecular Biology and Biochemistry, and did her postdoctoral trainings at St Jude Children’s Research Hospital (Tennessee, USA) as well as Massachusetts General Hospital (Boston, USA) before returning to Singapore to lead a research team at the National Cancer Center, focusing on the development of novel viral and cell-based vectors for targeted therapies against cancer. Building on her extensive experience, she now leads a team focused on developing CAR constructs and refining closed-system manufacturing processes to enhance the efficiency and safety of cell-based therapies.

Ryuichi Morishita, M.D., Ph.D., graduated Osaka University Medical School in 1987, and received Ph. D. from Osaka University in 1991. After following postdoctoral Fellow at Stanford University School of Medicine, he served as an Assistant Professor, Department of Geriatric Medicine, Osaka University Medical School from 1994 to 1998. Then, from 1998 to 2003, he was Associate Professor, Division of Gene Therapy Science, Osaka University Medical School. Then, he became Professor & Chairman of Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University Medical School from 2003 to present.

Dr. Lu-En Wai is an accomplished immunologist with over 15 years of expertise in immunology research, specializing in cellular immunotherapy, cancer, and Hepatitis B Virus (HBV) immunopathogenesis. She holds a Ph.D. in Immunology from Stanford University, earned under an A*STAR scholarship, with a focus on immune cell interactions in liver transplantation and cancer. Dr. Wai has made significant contributions at research institutions including the Singapore Immunology Network and Duke-NUS, where she investigated metastatic tumour microenvironment and HBV immunopathogenesis. Currently, as Senior Director of Research and Development at Lion TCR, she leads initiatives in T cell receptor (TCR) immunotherapy and diagnostic technologies aimed at combating viral infections and viral-related cancers. She is passionate about translating cutting-edge research into practical, clinically effective therapies.

Founder member of Zumutor Biologics. Designed and directed scientific, research, and technological operations to achieve overall R&D missions of Zumutor. My goal is to build a resilient scientific team at Zumutor, implementation of translational research and empower them to achieve height of their career.

A visionary, seasoned, and dynamic professional with extensive scientific, regulatory, and clinical expertise in developing biologic therapies within the field of immuno-oncology. I am dedicated to driving corporate growth and innovation by translating goals and objectives into actionable strategies that support Zumutor's mission of advancing a novel immuno-oncology biotherapeutic pipeline.

‍

Sacha is a cell biologist with over 18 years of experience in academia and the biotech/pharmaceutical industry, specializing in cell therapy development. She holds a PhD in Pharmacology from Monash University, with postdoctoral training in Regenerative Medicine at Stanford University, and was a Visiting Senior Research Fellow at Weill Cornell Medical College.​

Sacha has led the development of cell therapy platform technologies across multiple startups and played a key role in bringing cell therapies to market. Her work spans target validation, process development, GMP readiness, technology transfer, and commercialization, bringing a strong translational focus to the advancement of cell-based therapies.​

‍

Sheng Rong is a senior scientist at Nuevocor focusing on preclinical development of the company’s lead program. He received his PhD in Biology from MIT, where he adopted new molecular tools to improve existing preclinical models of cancer, and subsequently conducted postdoctoral research at IMCB, A*STAR, where he developed new models to study epigenetic dysregulation in cancer.

Dr. Kerwin Kwek Zeming is a research scientist at Singapore-MIT Alliance for Research and Technology (SMART) in Singapore. He holds a Ph.D. in Bioengineering from National University of Singapore with research interests in microfluidic technologies for precision cell sorting, profiling, and translational biomedical diagnostics. As a scientific innovator, Dr. Kwek has developed label-free microfluidic diagnostic tools for high-throughput, marker-free separation and single-cell cell analysis. His work has led to advances in immune cell profiling, with applications ranging from lab-on-a-chip diagnostics to neonatal sepsis screening. He has published in several leading journals, highlighting the impact of his contributions to the field.

Dr. Horak brings more than 20 years of experience in the global pharmaceutical industry, predominantly focused on oncology drug development, and is a board-certified medical oncologist. Prior to funding Tikva Allocell, Dr. Horak was Head of Global R&D and Chief Scientific at Tessa Therapeutics, a mid-stage cell therapy company in Singapore. For eight years, he was Chief Medical Officer and Chief Scientific Officer at Symphogen, a clinical-stage antibody company, and President of R&D at Enzon Pharmaceuticals, Inc. Dr. Horak has also held a number of senior research leadership positions in various pharmaceutical companies as well as at the National Cancer Institute (NCI), National Institutes of Health in US. During his career, Dr. Horak has advanced multiple oncology treatments into the clinic, and has successfully led a number of FDA new drug applications. 

Wei-Kai Hua received his Ph.D. from the Institute of Biopharmaceutical Sciences at National Yang-Ming University (NYMU), Taiwan, and carried out his postdoctoral training at City of Hope, California, USA. He has over 15 years of research experience in hematology and oncology. At GenomeFrontier Therapeutics, he has contributed to the development of advanced non-viral cell engineering and manufacturing technologies, including the robust Quantum Engine™ platform, CAR T cell manufacturing, and translational research. He played a principal role in advancing the GF-CART01 product through R&D and IND-enabling stages to clinical studies

‍

Dr. Jun Hu is currently Head of WuXi XDC Client Enabling Center of Excellence and Head of WuXi XDC Singapore Site Management, by leading a diversified team of talents, including CMC leaders, project managers and BDs, to help enable global ADC partners’ success on the CMC projects. He is also leading a team to support construct and manage WuXi XDC new facilities in Singapore Tuas site. He has over 13 years’ comprehensive experience on process development, GMP manufacturing, CMC management, business development as well as team management. Dr. Hu obtained his Ph.D. degree in Bioengineering from Tokyo Institute of Technology, and bachelor’s degree in chemical engineering from Tsinghua University. Before he joined WuXi Biologics/WuXi XDC he was working in Takeda Pharmaceutical Company Japan on process development and clinical GMP manufacturing.

Christopher Pawlak, Ph.D., had almost 2 decades in leadership position managing External Manufacturing and CDMOs in Pharmaceutical markets all over the globe. He oversaw global supplier management, external manufacturing operations, and strategic partnerships across the company’s biopharmaceutical network, manage finance of external manufacturing network. With over two decades of experience in pharmaceutical supply chain and procurement, he has led initiatives to enhance supplier performance, drive operational efficiency, and foster intercultural collaboration in global manufacturing.

In addition to his industry leadership, Dr. Pawlak serves as a lecturer and Executive Council member at the St. Gallen Integrated IMT Business School, reflecting his ongoing commitment to education and executive development. He is widely recognized as a thought leader in strategic supplier management, intercultural collaboration, and biomanufacturing innovation. 

Mr Kamyar Sadri brings over 25 years of global experience in digital, data and IT leadership, with a proven track record of driving enterprise-wide digital transformation across the pharmaceuticals, energy and technology sectors.

He specialises in translating business strategy into impactful digital roadmaps, architecting AI-enabled solutions and leading high-performing cross-functional teams across EMEA and Southeast Asia.

Throughout his career, Mr Kamyar has built digital centres of excellence from the ground up, managed multi-million-dollar portfolios and delivered scalable data platforms. His progression from IT infrastructure to digital transformation leadership reflects the dynamic evolution of technology’s role in business strategy.

Kamyar thrives in complex environments, whether navigating regulatory constraints, modernising IT infrastructure or pioneering cloud-first, open-source ecosystems. His leadership is grounded in a collaborative and agile mindset, with a strong emphasis on innovation, governance and the human side of digital transformation.

He is passionate about shaping data-driven futures, mentoring the next generation of leaders and sharing insights at global forums on how AI and advanced analytics are reshaping the business landscape.

Dr. Lucas Chan is a Molecular & Cell Biologist and has over 20 years of Research & Translational development of Cell & Gene Therapy products. He obtained his PhD at Imperial College London and was a Senior Investigator and Head of Manufacture for Advanced Therapies at King’s Health Partners in London where he played a lead role in establishing UK’s first GMP clinical viral vector capability. In Singapore, he founded CellVec Pte Ltd – a Viral Vector specialist CDMO that was the first of its kind to attain GMP accreditation. He is an elected Fellow of the Royal Society of Biology and served as an advisory member to Singapore Ministry of Health on Cell and Gene Therapy regulations. He’s currently an Independent Cell & Gene Therapy Advisor and Consultant as well as a visiting Senior Investigator at Yong Loo Lin School of Medicine at NUS

‍

Dr Akhil Prakash Chincholikar is a seasoned pharmaceutical R&D professional with 19 years of experience in organisations of international repute. He has successfully led cross-functional technical teams across various geographies, with a strong track record in pharmaceutical innovation and regulatory delivery. In his current role, he focuses on formulation development of small and large molecules (both oncology and non-oncology), pharmaceutical R&D portfolio management, and timely registration and delivery of products to market.

Elisa Cuevas is a neurodevelopmental and molecular biologist with 15+ years of experience in academia and the biotechnology industry. She earned her PhD from the Free University in Berlin, where she investigated the role of miRNA-target genes during CNS development using gene editing techniques. She then moved on to a postdoctoral fellowship at UCL, where she explored the use of cell and gene therapy to treat ophthalmological conditions. Prior to her current role, she served as the Laboratory Director at Axovia Therapeutics, a gene therapy company spun out from UCL. She joined 4basebio as Head of New Project Development (NPD) team and currently serves as Director of Client Projects, leveraging her scientific expertise to build and grow the company’s commercial portfolio.

Karen began her role as Chief Executive Officer of Touchlight in November 2020.

In her most recent role prior to joining Touchlight, Karen served as President, Business Unit Head, Mammalian and Microbial Development and Manufacturing for Lonza Pharma & Biotech. This business unit enabled Lonza’s customers to successfully develop and supply new biotherapeutics for patients by employing innovation in custom development and manufacturing across multiple technologies and throughout the drug life cycle.

Karen has worked in the CDMO area of the Life Sciences Industry for 31 years holding various roles at Celltech and Lonza leading Business Units, global Sales / Business Development, Licensing teams and Operational Quality. Karen has a BSc (Hons) in Applied Biology.

18+ years’ experience building companies and commercializing products including cell and gene therapies, synthetic biology platforms, scientific instrumentation, cell culture systems, and clinical manufacturing.

17+ years at Senti Biosciences as CTO and COO, leading cell therapy programs from synthetic biology design through IND filing and GMP manufacturing (both in-house and outsourced).

Ph.D. in Bio-engineering (UC Berkeley / UCSF)

‍

A/Prof Tan leads the Immune Cell Manufacturing group at BTI, A*STAR which focuses on developing deep capabilities in lab- and bioreactor-scale processes including media optimisation to support the production of unmodified or chimeric antigen receptor (CAR)-engineered allogeneic NK and gd T cells for cancer immunotherapy. This involved engineering feeder cells with immunostimulatory molecules and cytokines which promote the proliferation and anti-tumor potency of NK cells. He has filed several technology disclosures and previously led a joint laboratory with a local CDMO to establish scalable expansion of CAR virus-producing cells and CAR-T cells. His research has been supported by A*STAR, National Research Foundation, National Medical Research Council and industry funding where he led or co-led collaborative projects with biotechnology companies.

A/Prof Tan received his BSc and MSc in Physics from National University of Singapore (NUS) and PhD in Immunology from NUS Graduate School for Integrative Sciences and Engineering under the A*STAR Graduate Scholarship. He then completed postdoctoral training in Immunogenomics at John Curtin School of Medical Research, Australian National University before joining BTI as a research scientist. He was subsequently appointed Group Leader and currently serves as Adjunct Associate Professor with Food, Chemical and Biotechnology Cluster, Singapore Institute of Technology (SIT).

‍

Chethan A J is currently working as Assistant Director Quality Assurance and Regulatory Affairs at Center for Ocular Regeneration (CORE), LV Prasad Eye Institute, Hyderabad, India specializing in Quality Management System, Risk Management and Indian Regulatory Affairs. With over 13 years of experience in Cell and Gene therapy field, Chethan has involved and led the team in various aspects of CMC such as manufacturing, Quality Assurance and Regulatory Affairs. Under his leadership the CORE GMP manufacturing facility could achieve to get manufacturing and test license in form CT-11 for 5 unique cell therapy based products and Clinical trial license for Phase I trial for 2 unique cell therapy products in for CT-06 from Indian FDA, CDSCO. He is expert in deriving Quality Management System in Cell therapy products which meets the compliance to the required cGMP standards. He holds a master degree in Medical Biochemistry from Manipal University, MBA in Total Quality Management, Diploma in GMP, Six Sigma Green belt and certified Internal Auditor for ISO 9001:2015 QMS. He is an active member of Society of Quality Assurance (SQA) and Indian Society for Clinical Research (ISCR). Outside of work Chethan enjoys hiking, photography, sports & fitness.

Connect with Chethan in Linkedin: https://www.linkedin.com/in/chethan-jaiprakash-1559bb23

‍

CytoNiche has developed 3D TableTrix, a dissolvable, protein-based porous microcarrier system designed for large-scale manufacturing of adherent cells, critical for allogeneic cell therapies like Mesenchymal Stem Cells (MSCs) and cell-free therapies like exosomes. The 3D FloTrix Technology integrates these microcarriers into automated, closed bioreactor and cell processing systems to address scalability and purification challenges in cell therapy production. Ten billion MSCs could be produced in a single batch with 3D TableTrix microcarriers using serum-free xeno-free cell culture medium in 3D FloTrix vivaSPIN 15L bioreactor. Cells could be washed, concentrated, and formulated with 3D FloTrix vivaPREP PLUS and automatically filled and finished in different packaging options.  Discover how the first approved MSC drug in China employs this technology to achieve industrial-scale cell yields with a 3-stage process, compacted facility footprint (30 m²), and 80% reduction in workforce. CytoNiche aims to advance cell therapy manufacturing by offering a scalable, cost-effective solution that improves product quality and accessibility, benefiting sectors from regenerative medicine to vaccine production. This technology addresses critical bottlenecks in adherent cell processing, positioning it as a versatile tool for sustainable biopharmaceutical innovation.

Yen Choo is Associate Professor of Stem Cell Science and Regenerative Medicine at Lee Kong Chian School of Medicine (LKC Medicine), a joint medical school of Singapore’s Nanyang Technological University (NTU) and Imperial College London.

He is also Executive Director of co11ab@Novena, a BioMedtech incubator established jointly between NTU, the National Healthcare Group (HNG) and the Agency for Science, Technology and Research (A*STAR).

Prof. Choo serves on the board of the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), a GMP facility established for process development and manufacturing of cell-based therapeutics.

In addition to his academic career, he is a serial entrepreneur with over 25 years of experience in biotechnology companies developing advanced therapies.

His research, inventions and companies have been recognised by numerous prizes including The Queen’s Award in Enterprise for Innovation.

He holds a PhD in Molecular Biology from the University of Cambridge, and the MRC Laboratory of Molecular Biology together with Nobel laureate Aaron Klug.

‍

Dr Supannikar (Fai) Tawinwung is an Associate Professor of Pharmacology and Physiology at Chulalongkorn University and the co-founder of Cellmidi, a biotech spin-off focused on innovative CAR T cell therapies. Dr. Tawinwung has led the development of Thailand’s first GMP-compliant CAR T cell manufacturing platform and the country’s first-in-human trials in lymphoma, and pediatric brain tumors. Her research centers on engineering CAR T cells to overcome immunosuppressive environments in solid tumors. With a passion for translating science into accessible therapies, she bridges academic and entrepreneurial efforts to expand the reach of next-generation immunotherapies in Southeast Asia.

Siang-Chueng Koo is the Director, Innovative Medicine Regulatory Compliance at Johnson & Johnson, where she leads the quality compliance program for J&J manufacturing sites, marketing companies and distribution centers in the 14 Asia Pacific markets.  Proficient with global GMP, GCTP and GDP requirements, Siang also has a special interest on cell therapy.  Siang has 30 years of experience in the pharmaceutical sector in quality compliance, supply chain, procurement and consulting. As an Asian Compliance Leader with a Lean Sigma Black Belt, Siang is skilled with driving compliance improvement programs and remediation activities.  Before joining Johnson & Johnson, she worked at the Singapore Health Authority (Health Sciences Authority HSA), GSK and Abbott.  She was a part-time lecturer at National University of Singapore, holds a Master of Health Services Management from Curtin University of Technology, Australia and a Bachelor of Science (Pharmacy)(Hons) from National University of Singapore.

Dr. Ramin Baghirzade is a seasoned executive in the life sciences sector and currently serves as the Global Head of Commercial – Cell & Gene Therapy at Charles River Laboratories. With over 18 years of experience in healthcare and biopharma—including leadership roles at Roche, Lonza, and AGC Biologics—he brings deep expertise in cell and gene therapy and other advanced modalities. At Charles River, Dr. Baghirzade has played a pivotal role in expanding the company’s cell and gene therapy capabilities. He led the development and launch of several innovative manufacturing platforms, including eXpDNA™ (plasmid DNA), nAAVigation® (AAV), and Lentivation™ (lentiviral vectors), aimed at accelerating the path from discovery to commercialization. He was also instrumental in establishing the Charles River Accelerator Program (CAP) and Incubator Program (CIP)—two integrated initiatives that support early-stage ATMP developers through scientific guidance and scalable manufacturing solutions. Dr. Baghirzade holds a Ph.D. in Medical Sciences and an MBA and is a frequent industry speaker and recognized thought leader in the cell and gene therapy field.

Dr. Dinesh Kundu is the CEO & Co-founder of East Ocyon Bio, India’s pioneering biotech startup developing allogeneic CAR-NK and CAR-gamma delta T cell therapies for solid tumors, autoimmune, and rare diseases. A former Army physician with over 15 years in biopharma leadership across India and the US, he is driving innovation in affordable, off-the-shelf cell therapies for global health impact.

Dr. Sandy Qlintang, M.Biomed, is a prominent stem cell researcher and regenerative medicine expert in Indonesia. Since November 2009, he oversees research and development in stem cell and cancer diagnostics at the Stem Cell and Cancer Institute (SCI) under Kalbe Farma. He also leads Cell Therapy Manufacturing - under REGENIC brand, a leading stem cell therapy provider in Indonesia, at PT Bifarma Adiluhung, a subsidiary of Kalbe Farma. Dr. Qlintang has contributed to scientific literature, including research on mesenchymal stem cell secretome for lung fibrosis post-COVID-19 infection. His leadership and expertise have advanced stem cell applications and provided innovative solutions for degenerative diseases in Indonesia.

BhupalReddy Auothu is a seasoned leader in Cell and Gene Therapy with over 21 years of experience, currently serving as Site Head – CAR-T at Dr. Reddy’s. He has successfully led CMC development for four globally approved products—including therapies for rare diseases, TCRs, and CAR-Ts—and has submitted six INDs and four BLAs. Bhupal has built five GMP manufacturing facilities across the UK and US, and his expertise spans process innovation, regulatory strategy, technology evaluation, and global CDMO collaborations. He has a proven track record in scaling manufacturing capacity and accelerating product release timelines, contributing significantly to the advancement of Cell and Gene Therapy.

Sara has worked in the biotechnology field for over 15 years and found her niche in CDMOs having previously worked for Emergent BioSolutions, Patheon, and Cognate BioServices. As a part of Fujifilm Biotechnologies, Sara is the technical lead for Advanced Therapies Commercial team, working with commercial and CMC roles to design solutions that meet customer needs and ultimately ensure patients receive life-saving therapies. Sara is passionate about cell therapy, proudly supporting the commercialization efforts of both autologous and allogeneic programs. She holds a Bachelor of Science from Grand Valley State University and a Master of Science from Johns Hopkins University.

Shaun has expertise in T cell differentiation and chemokine receptor-mediated T cell migration. Work in his laboratory at the University of Adelaide has centred around understanding the biology of various members of the chemokine gene superfamily, in particular their role in resistance to infection, in cancer (solid tumour growth and metastasis) and in autoimmune diseases.

His research contribution has been recognised in industry and he has consulted for biotechnology and pharmaceutical companies. He is a past member of the Research Advisory Group for Cancer Council SA. Shaun is published in Nature, Nature Immunology, Nature Communications and Science Immunology, and has 10,000+ citations in the scientific literature.

Dr. Dunn has more than 20 years of experience in the fields of immunology, haematology, translational medicine and drug development. She was involved in the discovery of KappaMab, the company’s lead therapeutic antibody that targets a novel antigen called kappa myeloma antigen (KMA) found on the surface of malignant plasma cells but not on normal plasma cells. KappaMab has been used in three clinical trials, and its clinical development is ongoing. She was involved in the design, preclinical and upcoming clinical development of the chimeric antigen receptor that targets KMA (KMA.CAR T-cell).

She was a lead scientist in the discovery of the monoclonal antibody, LambdaMab, that targets lambda myeloma antigen (LMA) on malignant but not normal plasma cells. The chimeric antigen receptor that targets LMA (LMA.CAR T-cell) is in preclinical development.

Andy Holt is the Chief Commercial Officer (CCO) at Viralgen, an AAV manufacturing company based in San Sebastian, Spain. Holt has more than 15 years of experience in cell and gene therapy across the contract testing and manufacturing industries. He has worked with CGT companies to bring their therapies to the clinic and market and remains as passionate and awestruck about the potential of this industry as he was when he first had a chance to be a part of it. Prior to Viralgen, he was CCO of Ncardia, an iPSC solutions company. A native of Atlanta, Georgia, he holds a BSc in Applied Biology from Georgia Tech and calls Raleigh, North Carolina home.

Jennifer Kuan is Vice President of Operations at Bora Biologics Taiwan, with more than a decade of leadership in biologics. Beyond leading the design and startup of state-of-the-art facilities, she also guided her teams through process scale-up, across-site technology transfer, and successful first GMP manufacturing runs.

At Bora, Jennifer oversees site operations and was a core leader in the Tanvex merger. She is committed to building high-performing teams and ensuring the Taiwan site delivers reliable, agile, and high-quality solutions to global biopharma partners.

Dr. Sudeep Kumar is a biopharmaceutical expert with over 28 years of experience in the development and commercialization of recombinant proteins, vaccines, and diagnostic kits. He completed his postdoctoral research in Biotechnology at the University of Valencia and has worked across the entire product lifecycle—from R&D to manufacturing and regulatory approval.

Dr Kumar has a strong history of successfully navigating regulatory approvals with agencies such as WHO, US FDA, and SAPRA. He has been deeply involved in the development of novel therapeutics, including therapeutic proteins for cancer treatment, and played a key role in establishing the VLP technology platform for vaccines in India in collaboration with Novavax, USA.

‍He has held senior roles at Ranbaxy, Cadila Pharmaceuticals, Unichem and as Senior Vice President at Biological E. Ltd. in Hyderabad. Currently, he serves as Chief Operating Officer (COO) at Techinvention Life care Ltd, Mumbai where he leads traditional and innovative Vaccine development including mRNA based technology for Cancer therapy.

‍

Dr Cheng-Yi Kuo is the Vice General Manager of UWELL Biophama, Taiwan, and is involved with new product development/R&D, clinical development of cell & gene therapy and business development and corporate strategy. Dr Kuo has extensive experience in biological product development, quality requirements and regulatory approval and clinical trial research. Dr Kuo also worked in research and development as a drug and gene delivery scientist and managed a group of scientists in that area. He has 20 years of experience in biologics development, biological product life cycle, quality and regulatory affairs. He is also an assistant professor at National Defense Medical Center and Chung Yuan Christian University. He received his PhD in Pharmaceutical Biology from Monash University.